.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The HOT-HMV randomised trial evaluated whether home non-invasive ventilation added to home oxygen could improve outcomes after a life-threatening COPD exacerbation in patients with persistent hypercapnia. The study enrolled patients who remained hypercapnic after recovery from an acute episode and compared home oxygen alone with oxygen plus home NIV. Adding home NIV substantially prolonged the time to hospital readmission or death over the one-year follow-up period. The benefit supports a targeted approach to long-term ventilatory support: not every patient with COPD requires home NIV, but carefully selected patients with persistent hypercapnia after an acute decompensation may benefit. The trial is especially relevant because it links inpatient critical-care decisions with longer-term respiratory management. Persistent hypercapnia identifies a population with ongoing ventilatory insufficiency that may not be addressed by oxygen therapy alone. For clinicians, the practical message is to reassess gas exchange after recovery rather than assuming that correction of the acute exacerbation represents complete physiologic recovery. Home NIV requires appropriate patient selection, interface support, adherence monitoring and adequate ventilator settings. The study therefore supports an integrated pathway that begins with acute NIV in the hospital and, for selected patients, transitions to chronic ventilatory support aimed at reducing recurrent admissions and improving stability.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HOT-HMV randomised trial evaluated whether home non-invasive ventilation added to home oxygen could improve outcomes after a life-threatening COPD exacerbation in patients with persistent hypercapnia. The study enrolled patients who remained hypercapnic after recovery from an acute episode and compared home oxygen alone with oxygen plus home NIV. Adding home NIV substantially prolonged the time to hospital readmission or death over the one-year follow-up period. The benefit supports a targeted approach to long-term ventilatory support: not every patient with COPD requires home NIV, but carefully selected patients with persistent hypercapnia after an acute decompensation may benefit. The trial is especially relevant because it links inpatient critical-care decisions with longer-term respiratory management. Persistent hypercapnia identifies a population with ongoing ventilatory insufficiency that may not be addressed by oxygen therapy alone. For clinicians, the practical message is to reassess gas exchange after recovery rather than assuming that correction of the acute exacerbation represents complete physiologic recovery. Home NIV requires appropriate patient selection, interface support, adherence monitoring and adequate ventilator settings. The study therefore supports an integrated pathway that begins with acute NIV in the hospital and, for selected patients, transitions to chronic ventilatory support aimed at reducing recurrent admissions and improving stability.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
